Skip to main content

Table 1 Characteristics of all included researches

From: Efficacy and safety of botulinum toxin type A in distraction osteogenesis of the lower extremities: a meta-analysis of randomized controlled trials

Research

Country

Study design

Age at the time of surgery (years)

Classification of deformity

Gender (Male/Female)

Type of surgery

Location of surgery

Amount of lengthening (cm)

Rate of lengthening (mm/day)

Lengthening technique

Last follow-up time

Hamdy et al., 2009 [2]

Canada and United states

Randomized, double blinded, controlled trial

BoNT: 12.1 (4.5), control: 14 (3.4)

Congenital/acquired deformity; BoNT: 25/6, control: 18/3

BoNT: 20/11, control: 17/4

Lengthening / Angular correction and/or lengthening / Clubfoot correction; BoNT: 17/8/6, control: 8/10/3

Femur/tibia /foot; BoNT: 6/19/6, control: 8/9/4

BoNT: 5.9 (2.3), control: 4.1 (1.9)

NR

distraction with a fixator (either circular or uniplanar)

3 months post-frame removal

Lee et al., 2014 [15]

Republic of Korea

Randomized, double blinded, controlled trial

23 (range: 16–35)

NR

31/5

Bilateral tibial lengthening for familial short stature

Tibia

BoNT: 6.4 (range: 4.5–8.1), control: 6.4 (range: 4.3–8.1)

BoNT: 0.69 (range: 0.5–0.96), control: 0.68 (range: 0.51–0.97)

LATN or LON

Mean: 30 months (range: 24–39)

Hamdy et al., 2016 [16]

Canada and United states

Randomized, double blinded, controlled trial

BoNT: 11.8 (3.3), control: 13.3 (4.0)

Congenital/acquired deformity; BoNT: 47/12, control: 44/18

BoNT: 30/32, control: 42/21

Lengthening / deformity correction / deformity correction and lengthening; BoNT: 28/10/24, control: 38/5/20

Femur / tibia / foot / tibia and foot; BoNT: 18/35/7/2, control: 29/30/2/2

BoNT: 4 (1.9), control: 4.4 (1.6)

NR

distraction with a fixator (either circular or uniplanar)

3 months post-frame removal

Park et al., 2016 [17]

Republic of Korea

Randomized, double blinded, controlled trial

26 (8)

NR

35/9

Bilateral femoral lengthening for familial short stature

Femur

BoNT: 5.4 (0.6), control: 5.5 (0.6)

BoNT: 1.28 (0.14), control: 1.27 (0.12)

Intramedullary lengthening nails

Mean: 26 months (8, range: 14–40)

  1. Results are given as mean (SD), unless otherwise noted; BoNT Botulinum neurotoxin group, LATN Lengthening and then nailing, LON Lengthening over nail, NR Not reported, SD Standard deviation